@Article{Yuan2023,
journal="Journal of Contemporary Brachytherapy",
issn="1689-832X",
volume="15",
number="1",
year="2023",
title="Iodine-125 seed brachytherapy combined with pembrolizumab for advanced non-small-cell lung cancer after failure of first-line chemotherapy: A report of two cases and literature review",
abstract="Although immunotherapy regimens for advanced non-small-cell lung cancer (NSCLC) improve survival in selected sub-populations, their efficacy remains far from ideal due to underlying resistance; therefore, multimodal combination strategies are needed to optimize their efficacy. In our report, two patients with advanced NSCLC with negative targetable mutations, who had failed first-line chemotherapy were treated with combined therapy of computed tomography (CT)-guided percutaneous iodine-125 seed implantation and pembrolizumab. After combination treatment, both patients achieved partial response (PR), and sustained a long progression-free survival (PFS) without obvious therapy-related adverse reactions. Iodine-125 seeds bring no long-term adverse events and effectively amplify anti-tumor immune response induced by immunotherapy; thus, this combined therapy might be a promising alternative for NSCLC.",
author="Yuan, Mingli
and Wang, Liangchao
and Xiao, Yang
and Guo, Xiaoqun
and Hu, Yi",
pages="81--88",
doi="10.5114/jcb.2023.125582",
url="http://dx.doi.org/10.5114/jcb.2023.125582"
}